Impact News +++ Merck to collaborate with Tempus AI on precision oncology (SeekingAlpha) +++ TEMPUS AI Aktie -3,56%

THERAVANCE BIOPHARMA Aktie

>THERAVANCE BIO Aktienkurs

11.1 EUR -31.5% (TradegateBSX)

Ask: 12 EUR / 830 Stück

Bid: 11.7 EUR / 860 Stück

Tagesumsatz: 15 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>THERAVANCE BIO Performance

1 Woche: -4,9%

1 Monat: -7,1%

3 Monate: -1,9%

6 Monate: +31,6%

1 Jahr: +72,9%

laufendes Jahr: -1,9%

>THERAVANCE BIOPHARMA Aktie

Name:

THERAVANCE BIOPHARMA

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG8807B1068 / A1137V

Symbol/ Ticker:

0TB (Frankfurt) / TBPH (NASDAQ)

Kürzel:

FRA:0TB, ETR:0TB, 0TB:GR, NASDAQ:TBPH

Index:

Webseite:

https://www.theravance.co..

Profil:

Theravance Biopharma Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative medicines to address unmet clinical needs. Specializing in respirato..
>Volltext..

Marktkapitalisierung:

782.77 Mio. EUR

Unternehmenswert:

540.21 Mio. EUR

Umsatz:

67.99 Mio. EUR

EBITDA:

-25.07 Mio. EUR

Nettogewinn:

24.84 Mio. EUR

Gewinn je Aktie:

0.49 EUR

Schulden:

37.75 Mio. EUR

Liquide Mittel:

147.94 Mio. EUR

Operativer Cashflow:

206.28 Mio. EUR

Bargeldquote:

8.81

Umsatzwachstum:

20.61%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

THERAVANCE BIOPHARMA, THERAVANCE BIO

Letzte Datenerhebung:

03.03.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 50.67 Mio. St.

Frei handelbar: 93.38%

Leerverk. Aktien: 8.92%

Rückkaufquote: 0.19%

Mitarbeiter: 97

Umsatz/Mitarb.: 0.56 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 39.59%

Bewertung:

KGV: 33.8

KGV lG: 10.12

KUV: 12.67

KBV: 4.14

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 93.15%

Gewinnmarge: 36.53%

Operative Marge: -43.72%

Managementeffizenz:

Gesamtkaprendite: 7.61%

Eigenkaprendite: 14.03%

>Peer Group

Gesundheit

>THERAVANCE BIO Chart & Kurs - NASDAQ

>THERAVANCE BIO News

03.03.26 - 16:36	Theravance Biopharma: Aktie bricht nach gescheiterter Studie um 29 % ein (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.26 - 15:31	XFRA: 0TB: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN THERAVANCE BIOPHARMA 0TB KYG8807B1068 AB/FROM ONWARDS 03.03.2026 15:35 CET...

03.03.26 - 15:12	XFRA: 0TB: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL THERAVANCE BIOPHARMA 0TB KYG8807B1068 BAW/UFN...

03.03.26 - 14:39	XFRA: INSTRUMENT_SUSPENSION - KYG8807B1068 (XETRA)
	Instrument ID [7544] (0TB - KYG8807B1068) suspended...

03.03.26 - 14:33	Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions (PR Newswire)
	Phase 3 CYPRESS study did not meet the primary endpoint, the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at end of Q1 2026 including receipt of 2025 milestones; Theravance highly confident in......

28.01.26 - 20:30	Is the Options Market Predicting a Spike in Theravance Biopharma Stock? (Zacks)
	Investors need to pay close attention to TBPH stock based on the movements in the options market lately....

23.01.26 - 17:30	Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

06.01.26 - 17:30	Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

24.12.25 - 17:30	Here′s Why Theravance Biopharma (TBPH) is a Strong Growth Stock (Zacks)
	The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

22.12.25 - 17:30	Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here′s is How to Trade (Zacks)
	The mean of analysts' price targets for Theravance Bio (TBPH) points to a 42.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....

10.12.25 - 19:01	Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
	Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

08.12.25 - 19:45	Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? (Zacks)
	Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out....

06.12.25 - 02:01	Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 582501 USD (Insiderkauf)
	Farnum, Rhonda - Vorstand - Tag der Transaktion: 2025-12-03...

05.12.25 - 17:30	Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect? (Zacks)
	The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

05.12.25 - 17:30	Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term (Zacks)
	Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

20.11.25 - 17:03	Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 (PR Newswire)
	DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD......

19.11.25 - 17:30	Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

19.11.25 - 12:03	Theravance Biopharma to Participate in Upcoming Investor Conferences (PR Newswire)
	DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare Conference Location: Coral Gables, FL Format: Fireside Chat Date:......

11.11.25 - 20:48	Here′s Why Shares in Theravance Biopharma Exploded Today (Fool)
	The company is making excellent progress on all its strategic goals....

11.11.25 - 01:00	Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates (Zacks)
	Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das Übel nährt sich nur von seinesgleichen. Weise Menschen vergalten daher nicht Böses mit Bösem, sondern immer nur mit Gutem und brachten dadurch das Böse zu Fall. - Mohandas

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram